Phase 3 Clinical Trials With Primary Completion Dates in February 2026
This is a list of Phase 3 trials with primary completion dates in February 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ARDX | Ardelyx, Inc. | 2026-02-01 | Phase 3 | NCT06810167 | Assessing Tenapanor as a Treatment of CF-related Constipation. |
| CANF | Can-Fite BioPharma Ltd. | 2026-02-01 | Phase 3 | NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
| DAWN | Day One Biopharmaceuticals, Inc. | 2026-02-01 | Phase 3 | NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) |
| KOD | Kodiak Sciences Inc. | 2026-02-01 | Phase 3 | NCT06990399 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK |
| NMRA | Neumora Therapeutics, Inc. | 2026-02-01 | Phase 3 | NCT06058039 | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder |
| PHVS | Pharvaris N.V. | 2026-02-01 | Phase 3 | NCT05834777 | Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor |